A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

NCT02626234 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

cMET-dysregulated Advanced Solid Tumors

Interventions

DRUG: INC280
DRUG: digoxin
DRUG: rosuvastatin

Sponsor

Novartis Pharmaceuticals